Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list

• Main Authors: Martina Penazzato, Claire L. Townsend, Natella Rakhmanina, Yao Cheng, Moherndran Archary, Tim R. Cressey, Maria H. Kim, Victor Musiime, Anna Turkova, Theodore D. Ruel, Helena Rabie, Nandita Sugandhi, Pablo Rojo, Meg Doherty, Elaine J. Abrams, Elaine Abrams, Jintanat Ananworanich, Isabelle Andrieux-Meyer, Yodit Belew, Brookie Best, Rosa Bologna, Jessica Burry, Deborah Carpenter, Polly Clayden, Angela Colbers, Magda Conway, Timothy R. Cressey, Mutsa Dangarembizi, Shaffiq Essajee, Maribel Gonzalez Tome, Andrew Hill, Saye Khoo, Maria Kim, Linda Lewis, Janice Lee, Shahin Lockman, Imelda Mahaka, Mark H. Mirochnick, Lynne Mofenson, Mireille Muhimpundu, Angela Mushavi, Elizabeth Obimbo, Fernando Pascual, Carmen Perez Casas, Anton Pozniak, Theodore Ruel, Jonathan Schapiro, George Siberry, Teresa Beatriz Simione, Cheick Tidiane Tall, Francois Venter, Marissa Vicari, Jenny Walsh, Jacque Wambui, Melynda Watkins
• Format: Journal
• Published: 2019
• Subjects: Immunology and Microbiology; Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85071639026&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/66680
• Institution: Chiang Mai University

© 2019 Elsevier Ltd Despite considerable progress in paediatric HIV treatment and timely revision of global policies recommending the use of more effective and tolerable antiretroviral regimens, optimal antiretroviral formulations for infants, children, and adolescents remain limited. The Paediatric Antiretroviral Drug Optimization group reviews medium-term and long-term priorities for antiretroviral drug development to guide industry and other stakeholders on formulations most needed for low-income and middle-income countries. The group convened in December, 2018, to assess progress since the previous meeting and update the list of priority formulations. Issues relating to drug optimisation for neonatal prophylaxis and paediatric treatment, and those relating to the investigation of novel antiretrovirals in adolescents and pregnant and lactating women were also discussed. Continued focus on identifying, prioritising, and providing access to optimal antiretroviral formulations suitable for infants, children, and adolescents is key to ensuring that global HIV treatment targets can be met.